Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid in metastatic malignant melanoma
NCT00057616Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2002
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Revlimid Arm with Placebo Arm (2 arms). Primary endpoint: Overall Survival. Started Oct 2002; status: completed.
02
Drugs
lenalidomide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00057616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00057616.